Showing results (631-640 of 691) with videos related to

Sort By:
Pageof 70
Hepatology (Baltimore, Md.)|July 28, 2023
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)Mazen Noureddin, Emily Truong, Rebeca Mayo, et al.
The American Journal of Pathology|May 12, 2026
SIRPa cleavage is associated with inflammatory response, corticosteroid non-response, and worse prognosis in clinical and pre-clinical models of alcohol-associated hepatitisEthan R Steele, Dylan Nunn, David Malicote, et al.
Metabolic Syndrome and Related Disorders|January 27, 2022
Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver DiseaseAjay Duseja, Shivaram P Singh, Manu Mehta, et al.
The Lancet. Gastroenterology & Hepatology|November 18, 2022
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysisJingxuan Quek, Kai En Chan, Zhen Yu Wong, et al.
Nature Medicine|July 19, 2024
Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklistSiew S Lim, Zhila Semnani-Azad, Mario L Morieri, et al.
Clinical and Molecular Hepatology|May 20, 2026
The Natural History and Individualized Prediction of Liver Stiffness-Based Fibrosis Risk in MASLDYu Shi, Ruoqi Zhou, Seung Up Kim, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosisZobair M Younossi, Rohit Loomba, Quentin M Anstee, et al.
Gut|February 18, 2021
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trialGeltrude Mingrone, Annieke Cg van Baar, Jacques Devière, et al.
Pageof 70